| Code | CSB-RA012721MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to NGM-438, targeting LAIR1 (Leukocyte-Associated Immunoglobulin-like Receptor 1), an inhibitory receptor expressed on immune cells including NK cells, T cells, and B cells. LAIR1 functions as an immune checkpoint by binding to collagen and collagen-like proteins, delivering inhibitory signals that dampen immune cell activation and effector functions. This receptor plays a critical role in maintaining immune homeostasis and self-tolerance, with dysregulation implicated in autoimmune disorders, chronic infections, and cancer immune evasion where tumor-associated collagen can suppress anti-tumor immunity.
NGM-438 is a clinical-stage therapeutic antibody that blocks LAIR1-collagen interactions, thereby releasing the brake on immune cell activity and enhancing anti-tumor responses. This biosimilar provides researchers with a valuable tool for investigating LAIR1-mediated immune regulation, exploring therapeutic strategies for cancer immunotherapy, studying checkpoint inhibitor mechanisms, and evaluating combination approaches with other immunomodulatory agents. The antibody supports studies aimed at understanding how LAIR1 blockade can restore immune cell function in suppressive tumor microenvironments.
There are currently no reviews for this product.